Daraxonrasib costs $39,800 monthly as access expands
Approved daraxonrasib costs $39,800 monthly; 2,000+ patients already accessed it.
Event / Science
Daraxonrasib Pancreatic Cancer Drug Approval
FDA approved Revolution Medicines' daraxonrasib (Rasonque) on August 27, 2026, as the first drug targeting RAS mutations in metastatic pancreatic cancer. The daily pill doubled survival time to 13.2 months versus 6.7 months with chemotherapy, reducing mortality risk by 60%. Priced at $39,800 per month, it addresses a critical gap in pancreatic cancer treatment where five-year survival remains around 13%.
3 reported locations
Daily activity
2 articles0 articles
2026-08-27 to 2026-11-08 · UTC publication dates
Coverage begins 27 Aug, 00:05 UTC
Follow the documented timeline or explore the related reporting.
What happened
Over 2,000 patients accessed daraxonrasib through expanded-access program
Before official FDA approval, Revolution Medicines provided daraxonrasib through an expanded-access program for eligible patients with previously treated metastatic pancreatic cancer. More than 2,000 patients had enrolled in this program by the time of approval in August 2026.
Daraxonrasib approved with expedited FDA timeline
The FDA approved daraxonrasib more than six months ahead of its user-fee deadline. The drug received Breakthrough Therapy and Orphan Drug designations, Priority Review status, and consideration through the FDA Commissioner's National Priority Voucher pilot program, reflecting the agency's recognition of an unmet medical need in pancreatic cancer treatment.
FDA approves daraxonrasib for metastatic pancreatic cancer
The Food and Drug Administration approved Revolution Medicines' daraxonrasib (brand name Rasonque) on Wednesday as a treatment for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for multiagent systemic therapy. The drug is the first in a new class designed to broadly inhibit RAS variants, which drive approximately 90% of pancreatic cancers.
Daraxonrasib targets KRAS mutations in pancreatic cancer
Daraxonrasib is designed to block active forms of RAS proteins, specifically targeting KRAS mutations found in more than 90% of pancreatic adenocarcinoma cases. The drug uses a molecular glue mechanism to bind with multiple KRAS subtypes, addressing a longstanding challenge in cancer treatment as KRAS was previously considered difficult to target with drugs due to its smooth protein structure.
Daraxonrasib doubles survival time in pancreatic cancer patients
In the Phase 3 RASolute 302 clinical trial involving 500 patients with previously treated metastatic pancreatic cancer, patients receiving daraxonrasib achieved a median survival of 13.2 months compared to 6.7 months for those receiving standard chemotherapy. The drug reduced the risk of death by 60% and delayed disease progression to 7.2 months versus 3.6 months with chemotherapy.
Rasonque priced at $39,800 for 30-day supply
Revolution Medicines set the wholesale acquisition cost for Rasonque at $39,800 for a 30-day supply at the recommended dosage. This represents the drug's list price; actual out-of-pocket costs will vary based on insurance coverage. The company is offering patient support through its ON Path program and copay assistance for eligible patients with commercial insurance.
Daraxonrasib results presented at 2026 ASCO Annual Meeting
Dr. Brian M. Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, presented the RASolute 302 trial results at the 2026 American Society of Clinical Oncology Annual Meeting plenary session in Chicago on May 31. When Wolpin presented data showing the drug reduced death risk by 60%, the packed auditorium erupted in applause.
Daraxonrasib shows manageable side effect profile
In clinical trials, daraxonrasib was associated with fewer severe side effects compared to chemotherapy. Common adverse effects included rash, diarrhea, mouth sores, nausea, fatigue, vomiting, and abdominal pain. The drug does not require a companion diagnostic test and can be used regardless of a patient's RAS mutation status.
Read the coverage
2 alternative perspectives
FDA approves daraxonrasib, targeting KRAS mutations in pancreatic cancer
FDA approved daraxonrasib for metastatic pancreatic cancer, doubling survival in KRAS-mutant patients with manageable side effects.